A 24-WEEK RANDOMIZED, DOUBLE-BLIND, MULTI-CENTER, ACTIVE-CONTROLLED (PIOGLITA

24 周随机、双盲、多中心、主动控制（PIOGLITA

• 批准号: 7379159
• 负责人: HELMUT O STEINBERG
• 金额: $ 0.08万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7379159
• 关键词: 24; WEEK; RANDOMIZED; DOUBLE; BLIND

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. There is a need for new and better anti-diabetic drugs. The aim of this multi national, multicenter study is to compare the efficacy, safety and tolerability of the new ppar gamma activator tesaglitazar with standard therapy. Preliminary data suggest that tesaglitazar is at least as effective as standard therapy and may have additional effects to lower lipids in type 2 diabetic subjects.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。需要新的和更好的抗糖尿病药物。这项多国、多中心研究的目的是比较新型ppar γ激活剂tesaglitazar与标准治疗的疗效、安全性和耐受性。初步数据表明，tesaglitazar至少与标准治疗一样有效，并且可能对2型糖尿病受试者的降脂有额外作用。